Oklahoma Senate Bill SB1822

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Medical marijuana licenses; authorizing certain research license; requiring promulgation of certain rules. Effective date.

Summary

SB1822 authorizes the Oklahoma Medical Marijuana Authority (OMMA) to create a new research license focused on collecting, analyzing, and monitoring patient-reported outcomes related to medical marijuana use. The license would allow approved licensees to evaluate medical marijuana products available in Oklahoma and to conduct studies such as surveys and data collection on the effects of medical marijuana on medical conditions. The bill limits eligibility for the research license to research institutions, health care organizations, licensed cannabis businesses, and private research companies. It also sets an initial nonrefundable application fee of $500 and directs OMMA to adopt rules governing license issuance, application approval, compliance monitoring, and reporting requirements. The act would take effect November 1, 2026.

Impact

If enacted, SB1822 would add a new research-license category to Oklahoma’s medical marijuana regulatory framework in Title 63, giving OMMA explicit authority to license and oversee patient-outcome research involving medical marijuana. It would affect medical marijuana regulators, research entities, health care organizations, cannabis businesses, and private research firms by creating a formal pathway to conduct studies and by imposing fee, compliance, and reporting obligations under agency rules.

Sentiment

The available record shows little overt debate or recorded vote activity, so the overall sentiment appears neutral to favorable based on the bill’s purpose. The measure is framed as a research and data-collection tool rather than a restriction on access, suggesting support from stakeholders interested in evidence-based evaluation of medical marijuana. No committee transcript is available to indicate organized opposition or amendments.

Contention

The main potential points of contention are likely to be the scope of OMMA’s regulatory authority, the types of entities allowed to hold the license, and the handling of patient data and research oversight. Cannabis businesses and private research companies may favor the new license as a way to participate in studies, while privacy advocates or critics of expanded marijuana research infrastructure could raise concerns about compliance, reporting burdens, or the use of patient-reported outcomes. However, no specific objections are documented in the available materials.